Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model
<p><strong>Background</strong> The first gene therapy for an inherited retinal dystrophy recently received market approval in the United States; multiple other gene therapies are in the clinical pipeline. Thus far, gene therapy has commanded prices in the range of USD 500,000 to ov...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer Nature
2019
|